The two companies plan to explore other synergies in theirofferings as well. Gretchen Dock, a spokesperson for Phase Forward, declined tocomment specifically on possible future developments because her company ispublicly traded and this is a new business relationship. Albano, however, wasable to offer at least one area where he sees a great deal of future potential,and that is in true integration of clinical trial data entry and drug safetyreporting.
"There's a big demand inthe marketplace for a really integrated solution where electronic data captureproducts would integrate with drug safety so that when an investigative siteenters info in the system, they get a seamless transition for entering data forthe trial and simultaneously reporting safety events they encounter," Albanoexplains. "Typically, companies have had to use two separate products to dothat, but working with Phase Forward may offer the chance to eliminate thatproblem because they have software suites in both areas."
